Brian Windsor - Aileron Therapeutics COO President
| ALRN Stock | USD 2.12 0.02 0.93% |
President
Brian Windsor is COO President of Aileron Therapeutics
| Age | 57 |
| Address | 12407 N. Mopac Expy., Austin, TX, United States, 78758 |
| Phone | 737 802 1989 |
| Web | https://www.aileronrx.com |
Aileron Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2586) % which means that it has lost $0.2586 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4432) %, meaning that it created substantial loss on money invested by shareholders. Aileron Therapeutics' management efficiency ratios could be used to measure how well Aileron Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of December 2024, Return On Tangible Assets is likely to drop to -0.81. In addition to that, Return On Capital Employed is likely to drop to -0.17. At this time, Aileron Therapeutics' Intangible Assets are very stable compared to the past year. As of the 11th of December 2024, Intangibles To Total Assets is likely to grow to 0.76, while Other Assets are likely to drop 0.00.Similar Executives
| Found 1 records | PRESIDENT Age | ||
| Leslie Robbins | CytomX Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.26 |
Aileron Therapeutics Leadership Team
Elected by the shareholders, the Aileron Therapeutics' board of directors comprises two types of representatives: Aileron Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aileron. The board's role is to monitor Aileron Therapeutics' management team and ensure that shareholders' interests are well served. Aileron Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aileron Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Garner, Principal Officer | ||
| Allen Annis, Vice President - Biophysical and Analytical Technologies | ||
| James Windsor, COO President | ||
| Brian Windsor, COO President |
Aileron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aileron Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 28.67 M | ||||
| Shares Outstanding | 21.67 M | ||||
| Shares Owned By Insiders | 0.60 % | ||||
| Shares Owned By Institutions | 28.47 % | ||||
| Number Of Shares Shorted | 178.8 K | ||||
| Price To Earning | (0.31) X | ||||
| Price To Book | 0.92 X | ||||
| Gross Profit | (17.01 M) |
Pair Trading with Aileron Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aileron Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aileron Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Aileron Stock
| 0.79 | DYAI | Dyadic International | PairCorr |
| 0.58 | ESPR | Esperion Therapeutics | PairCorr |
| 0.38 | BMY | Bristol Myers Squibb | PairCorr |
The ability to find closely correlated positions to Aileron Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aileron Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aileron Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aileron Therapeutics to buy it.
The correlation of Aileron Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aileron Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aileron Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aileron Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Return On Assets (0.26) | Return On Equity (0.44) |
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.